Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionAssenagon Asset Management S.A.
Latest Disclosed Ownership7,927 shares
Latest Disclosed Value $ 235,511
Assenagon Asset Management S.A. reports 98.10% decrease in ownership of TVTX / Travere Therapeutics, Inc.

On April 20, 2026 - Assenagon Asset Management S.A. filed a 13F-HR form disclosing ownership of 7,927 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $235,511 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 9, 2026 disclosing 417,742 shares of Travere Therapeutics, Inc.. This represents a change in shares of -98.10% during the quarter. The current value of the position is $358,300 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-20 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 7,927 -409,815 -98.10 236 -98.53 0.0004
2026-01-09 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 417,742 324,387 347.48 15,962 615.42 0.0220
2025-10-07 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 93,355 -1,009,720 -91.54 2,231 -86.33 0.0031
2025-07-11 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,103,075 689,561 166.76 16,326 120.31 0.0242
2025-04-15 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 413,514 -116,999 -22.05 7,410 -19.81 0.0124
2025-01-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 530,513 -844,009 -61.40 9,242 -51.94 0.0149
2024-10-23 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,374,522 -839,577 -37.92 19,230 5.66 0.0354
2024-07-18 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 2,214,099 1,995,419 912.48 18,200 979.42 0.0405
2024-04-24 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 218,680 -35,371 -13.92 1,686 -26.15 0.0040
2024-01-17 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 254,051 0 0.00 2,284 0.53 0.0061
2023-11-06 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 254,051 -843,994 -76.86 2,271 -86.53 0.0070
2023-07-25 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,098,045 -560,644 -33.80 16,866 -54.79 0.0583
2023-04-18 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 1,658,689 791,270 91.22 37,304 207,138.89 0.1324
2023-01-12 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 867,419 -57,095 -6.18 18 -99.92 0.0658
2022-10-27 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 924,514 -25,951 -2.73 22,780 -1.09 0.0874
2022-07-27 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 950,465 639,114 205.27 23,030 187.01 0.0854
2022-04-25 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 311,351 115,820 59.23 8,024 32.21 0.0223
2022-02-01 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 195,531 195,531 6,069 0.0176
2021-02-01 2020-12-31 13F RETROPHIN COM 761299106 0 -359,761 -100.00 0 -100.00
2020-10-07 2020-09-30 13F RETROPHIN COM 761299106 359,761 195,592 119.14 6,641 98.18 0.0373
2020-07-21 2020-06-30 13F RETROPHIN COM 761299106 164,169 -266,277 -61.86 3,351 -46.64 0.0215
2020-04-17 2020-03-31 13F RETROPHIN COM 761299106 430,446 430,446 6,280 0.0503
2019-04-26 2019-03-31 13F RETROPHIN COM 761299106 0 -21,808 -100.00 0 -100.00
2019-01-23 2018-12-31 13F RETROPHIN COM 761299106 21,808 21,808 494 0.0056
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.